Jpmorgan Chase & CO Aptevo Therapeutics Inc. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Dec 26, 2024	BUY	$0.17 - $0.38 $322 - $720	1,897 New	1,897 $0
Q4 2023 Feb 12, 2024	SELL	$0.17 - $0.38 $1 - $3	-10 Reduced 0.52%	1,897 $0
Q3 2023 Nov 14, 2023	BUY	$0.31 - $1.78 $591 - $3,394	1,907 New	1,907 $0
Q2 2022 Aug 11, 2022	SELL	$3.26 - $6.3 $665 - $1,285	-204 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$4.48 - $8.42 $913 - $1,717	204 New	204 $1,000

Ticker APVO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,090,640
Market Cap $24.2M
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.